Lenalidomide in multiple myeloma

References

• Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc.78, 21–33 (2003).
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BGM et al. International staging system for multiple myeloma. J. Clin. Oncol.23, 3412–3420 (2005).
   PubMed Web of Science ®Google Scholar
• Bartlett JB, Michael A, Clarke IA et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br. J. Cancer90, 955–961 (2004).
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson J et al. A Phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br. J. Haematol.127, 165–172 (2004).
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson JR et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer103, 1195–2000 (2005).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J et al. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med.348, 2609–2617 (2003).
   PubMed Web of Science ®Google Scholar
• Hovenga S, Daenen SMGJ, de Wolf JTM et al. Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective Phase II study. Ann. Hematol.84, 311–316 (2005).
   PubMed Web of Science ®Google Scholar
• Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br. J. Haematol.109, 89–96 (2000).
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Thomson K, D’Sa S et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br. J. Haematol.129, 763–770 (2005).
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med.341, 1565–1571 (1999).
   PubMed Web of Science ®Google Scholar
• Teo SK, Stirling DI, Zeldis JB. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov. Today10, 107–114 (2005).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol.24, 431–436 (2006).
   PubMed Web of Science ®Google Scholar
• Clark TE, Edom N, Larson J, Lindsey LJ. Thalomid® (thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Saf.24, 87–117 (2001).
   PubMed Web of Science ®Google Scholar
• Zeldis JB, Williams BA, Thomas SD, Elsayed ME. S.T.E.P.S.™: a comprehensive program for controlling and monitoring access to thalidomide. Clin. Ther.21, 319–330 (1999).
   PubMed Web of Science ®Google Scholar
• Catley L, Weisberg E, Tai Y-T et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood102, 2615–2622 (2003).
   PubMed Web of Science ®Google Scholar
• Lin B, Podar K, Gupta D et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res.62, 5019–5026 (2002).
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades NS, McMullan CJ et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl Acad. Sci. USA101, 540–545 (2004).
   PubMed Web of Science ®Google Scholar
• Beaupre DM, Cepero E, Obeng EA, Boise LH, Lichtenheld MG. R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Mol. Cancer Ther.3, 179–186 (2004).
   PubMed Web of Science ®Google Scholar
• Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat. Rev. Cancer2, 927–937 (2002).
   PubMed Web of Science ®Google Scholar
• Hideshima T, Podar K, Chauhan D et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene23, 8766–8776 (2004).
   PubMed Web of Science ®Google Scholar
• Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J. Exp. Med.173, 699–703 (1991).
   PubMed Web of Science ®Google Scholar
• Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer4, 314–322 (2004).
   PubMed Web of Science ®Google Scholar
• List A, Kurtin S, Roe DJ et al. Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med.352, 549–557 (2005).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Schlossman RL, Weller E et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood100, 3063–3067 (2002).
   PubMed Web of Science ®Google Scholar
• Muller GW, Chen R, Huang S-Y et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-α production. Bioorg. Med. Chem. Lett.9, 1625–1630 (1999).
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood98, 210–216 (2001).
   PubMed Web of Science ®Google Scholar
• Richardson P, Hideshima T, Anderson K. Thalidomide: emerging role in cancer medicine. Annu. Rev. Med.53, 629–657 (2002).
   PubMed Web of Science ®Google Scholar
• Dredge K, Marriott JB, Macdonald CD et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br. J. Cancer87, 1166–1172 (2002).
   PubMed Web of Science ®Google Scholar
• Lentzsch S, LeBlanc R, Podar K et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.Leukemia17, 41–44 (2003).
   PubMed Web of Science ®Google Scholar
• Dredge K, Horsfall R, Robinson SP et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.Microvasc. Res.69, 56–63 (2005).
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood96, 2943–2950 (2000).
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood99, 4525–4530 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson KC. Lenalidomide and thalidomide: mechanisms of action – similarities and differences. Semin. Hematol.42, S3–S8 (2005).
   PubMed Web of Science ®Google Scholar
• Bartlett JB, Tozer A, Stirling D, Zeldis JB. Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide. Br. J. Cancer93, 613–619 (2005).
   PubMed Web of Science ®Google Scholar
• Zangari M, Tricot G, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B. Results of Phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT). Blood98, 775a (2001).
   Web of Science ®Google Scholar
• Zangari M, Barlogie B, Jacobson J et al. Revlimid 25 mg (REV 25) × 20 versus 50 mg (REV 50) × 10 q28 days with bridging of 5 mg × 10 versus 10 mg × 5 as post-transplant salvage therapy for multiple myeloma. Blood102, 450a (2003).
   Google Scholar
• Richardson PG, Jagannath S, Schlossman R et al. A multi-center, randomized, Phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for treatment of relapsed or refractory multiple myeloma. Blood102, 235a (2003).
   Google Scholar
• Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood106, 4050–4053 (2005).
   PubMed Web of Science ®Google Scholar
• Dimopoulous M, Weber D, Chen C et al. Evaluating oral lenalidomide (Revlimid®) and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica90, 160 (2005).
   Google Scholar
• Niesvizky R, Spencer A, Wang M et al. Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin. J. Clin. Oncol.24, 423S (2006).
   Google Scholar
• Gerecke C, Knop S, Topp M et al. A multicenter Phase I/II trial evaluating the safety and efficacy of lenalidomide (Revlimid, CC-5013) in combination with doxorubicin and dexamethasone (RAD) in patients with relapsed or refractory multiple myeloma. Blood106, 367b (2005).
   Google Scholar
• Niesvizky R, Jayabalan DS, Furst JR et al. Clarithromycin, lenalidomide and dexamethasone combination therapy as primary treatment of multiple myeloma. J. Clin. Oncol.24, S433 (2006).
   Google Scholar
• Baz R, Choueiri TK, Jawde RA et al. Doxil (D), vincristine (V), reduced frequency dexamethasone (d) and Revlimid® (DVd-R) results in a high response rate in patients with refractory multiple myeloma (RMM). Blood106, 719a (2005).
   Google Scholar
• Richardson P, Schlossman R, Munshi N et al. A Phase 1 trial of lenalidomide (Revlimid®) with bortezomib (Velcade®) in relapsed and refractory multiple myeloma. Blood106, 110a (2005).
   PubMed Web of Science ®Google Scholar